Patents Assigned to Skandigen AB
  • Artificial gene coding for authentic human serum albumin, use thereof and method
    Patent number: 5879907
    Abstract: A structural gene coding for authentic human serum albumin, --optionally supplemented by an upstream triplet coding for methionine and optionally extended by a synthetic prepro.sup.x -leader-coding sequence--, wherein the codons of the nucleotide sequence have been selected with regard to a non-human host, e.g. yeast, chosen for expression of authentic human serum albumin, is disclosed.Additionally there is disclosed a method of producing said gene.There are also disclosed a recombinant DNA molecule comprising said strucural gene inserted into a vector, and a host transformed with said recombinant DNA molecule.Furthermore there are disclosed a method of producing authentic human serum albumin, an authentic human serum albumin resulting from said method, and a pharmaceutical composition comprising said resulting human serum albumin.
    Type: Grant
    Filed: May 13, 1992
    Date of Patent: March 9, 1999
    Assignees: Skandigen AB, MTA Szegedi Biologiai Kozpontja, Vepex Contractor Ltd.
    Inventors: Bertil Aberg, Andras Simoncsits, Miklos Kalman, Imre Cserpan, Gyorgy Bajszar
  • Cell proliferation matrix and use thereof
    Patent number: 5432167
    Abstract: A cell proliferation matrix consisting of an aqueous gel of hyaluronic acid or a pharmaceutically acceptable salt thereof which is free from production-related animal DNA and RNA and which is in a dissolved state, is disclosed. Further, the use of hyaluronic acid or a pharmaceutically acceptable salt thereof for the preparation of a cell proliferation matrix according to the invention, for the treatment of at least one of bone fractures, Ulcus Varicosum Cruris, and ulcera caused by Diabetes Mellitus and other diseases (e.g. Decubitus) with impaired arterial blood flow, is described. Also, a method of treating at least one of bone fractures, Ulcus Varicosum Cruris, and ulcera caused by Diabetes Mellitus and other diseases with impaired arterial blood flow is disclosed.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: July 11, 1995
    Assignee: Skandigen AB
    Inventor: Kerstin Brismar
  • Antibacterial polypeptides
    Patent number: 5096886
    Abstract: A polypeptide having bactericidal activity, particularly against gram-negative bacteria, has been isolated from pig intestine. The porcine cecropin has the amino acid sequence: H.sub.2 N-Ser-Trp-Leu-Ser-Lys-Thr-Ala-Lys-Lys-Leu-Glu-Asn-Ser-AlaLys-Lys-Arg-Ile-S er-Glu-Gly-Ile-Ala-Ile-Ala-Ile-Gln-Gly-Gly-Pro-Arg-COOh. Pharmaceutical compositions containing such poypeptides, or functional derivatives thereof, are useful in therapeutic and prophylactic methods for inhibiting bacterial growth.
    Type: Grant
    Filed: May 31, 1990
    Date of Patent: March 17, 1992
    Assignees: Kabigen AB, Skandigen AB
    Inventors: Hans G. Boman, Hans Jornvall, Jong-Youn Lee, Viktor Mutt
  • Human intestinal hormone and its use
    Patent number: 4806336
    Abstract: A human intestinal hormone having the following peptide structure: His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Le u-Gln-Arg-Leu-Gln-Gly-Leu-Val-NH.sub. 2 ; compositions containing such hormone; and a method of stimulating pancreatic secretion.
    Type: Grant
    Filed: November 7, 1986
    Date of Patent: February 21, 1989
    Assignee: KabiGen AB and Skandigen AB
    Inventors: Mats Carlquist, Hans Jornvall, Wolf-Georg Forssmann, Lars Thulin, Catja Johansson, Viktor Mutt